Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy

Journal of Gastroenterology

Volumn 44, Issue SUPPL. 19, 2009, Pages 64-71

  Maiden, Laurence ^a  

^a MAIDSTONE HOSPITAL   (United Kingdom)

Author keywords

Capsule endoscopy; COX 2 inhibitor; NSAID; NSAID enteropathy

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

ADULT; AGED; ANGIODYSPLASIA; CAPSULE ENDOSCOPY; CONTROLLED STUDY; DRUG SAFETY; ENTERITIS; ENTEROPATHY; FEMALE; HUMAN; INTESTINAL BLEEDING; INTESTINE OBSTRUCTION; INTESTINE POLYP; INTESTINE ULCER; LONG TERM CARE; LOW BACK PAIN; LOW DRUG DOSE; LYMPHANGIECTASIS; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PETECHIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SHORT COURSE THERAPY; SMALL INTESTINE DISEASE; STOMACH INJURY; STOMACH PROTECTION; VOLUNTEER;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPSULE ENDOSCOPY; CONTROLLED CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; DELAYED-ACTION PREPARATIONS; DICLOFENAC; FEMALE; HUMANS; INTESTINAL DISEASES; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 58849140520     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2248-8     Document Type: Review

References (54)

1. Stone E. An account of the success of the bark of the willow in the cure of agues. Philos Trans R Soc Lond 1763;53:195-200.
2. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
3. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990;300:278-284.
4. Raskin J. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999;106(5B):3S-12S.
5. Langman M, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994;343:1075-1078.
6. Fries J, Williams C, Bloch D, Michel B. Nonsteroidal anti-inflammatory drug gastropathy: Incidence and risk factors model. Am J Med 1991;91:213-222.
7. Raz A, Wyche A, Needleman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci USA 1989;86:2076-2085.
8. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1992;266:12866-12872.
9. Ferraz JG, Sharkey KA, Reuter BK, et al. Induction of cyclooxygenase 1 and 2 in rat stomach during endotoxemia: Role in resistance to damage. Gastroenterology 1997;113:195-204.
10. Rainsford K. Gastrointestinal adaptation, gastrointestinal injury by NSAIDs. Regulation of eicosanoids and mucosal protection from NSAIDs. In: Rainsford KD, editor. Side effects of antiinflammatory drugs, vol 4. Dordrecht: Kluwer; 1997. 197-205.
11. Vaananen PM, Meddings JB, Wallace JL. Role of oxygen-derived free radicals in indomethacin-induced gastric injury. Am J Physiol 1991;261:G470-G475.
12. Sigthorsson G, Tibble J, Mahmud T, Bjarnason I. NSAID-induced gastrointestinal damage: The biochemical consequences of the "ion trapping" hypothesis. Imflammopharmacology 2000;8:31-41.
13. Hogben CAM, Schanker LS, Tocco DJ, et al. Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther 1957;120:540-545.
14. Somasundaram S, Macpherson AJ, Hayllar J, Saratchandra P, Bjarnason I. Enterocyte mitochondrial damage due to NSAIDs in the rat. Gut 1992;33(suppl):S5.
15. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 1993;104:1832-1847.
16. Lichtenberger LM, Wang ZM, Romero JJ, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995;1:154-158.
17. Mahmud T, Scott D, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996;55:211-213.
18. Morris AJ, Wasson LA, MacKenzie JF. Small bowel enteroscopy in undiagnosed gastrointestinal blood loss. Gut 1992;33:887-889.
19. Bjarnason I, Zanelli G, Prouse P, Smethurst P, Levi S, Gumpel MJ, Levi AJ. Blood and protein loss via small intestinal inflammation induced by nonsteroidal anti-inflammatory drugs. Lancet 1987;2:711-714.
20. Bjarnason I, Zanelli G, Smethurst P, Burke M, Gumpel MJ, Price AB, Levi AJ. Clinico-pathological features of nonsteroidal antiinflammatory drug induced small intestinal strictures. Gastroenterology 1988;94:1070-1074.
21. Lang J, Price AB, Levi AJ, Burke M, Gumpel JM, Bjarnason I. Diaphragm disease: Pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. J Clin Pathol 1988;41:516-526.
22. Bjarnason I, Williams P, So A, Zanelli G, Levi AJ, Gumpel MJ, et al. Intestinal permeability and inflammation in rheumatoid arthritis; effects of non-steroidal anti-inflammatory drugs. Lancet 1984;2:1171-1174.
23. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. The effect of NSAIDs and prostaglandins on the permeability of the human small intestine. Gut 1986;27:1292-1297.
24. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989;34:407-411.
25. Davies GR, Rampton DS. The pro-drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1991;5:593-598.
26. Davies GR, Rampton DS. Relevance of intestinal bacteria, prostaglandins and pro-drug administration to NSAID induced increase in gut permeability (abstract). Gut 1991;32:A1224.
27. Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, DeLacey G, et al. Nonsteroidal antiinflammatory drug induced intestinal inflammation in humans. Gastroenterology 1987;93:480-489.
28. Segal AW, Isenberg DA, Hajirousou V, Tolfree S, Clark J, Snaith ML. Preliminary evidence for gut involvement in the pathogenesis of rheumatoid arthritis? Br J Rheumatol 1986;25:162-166.
29. Rooney PJ, Jenkins RT, Smith KM, Coates G. 111-Indiumlabelled polymorphonuclear leucocyte scans in rheumatoid arthritis: An important clinical cause of false positive results. Br J Rheumatol 1986;25:167-170.
30. Shah AA, Thjodleifsson B, Murray FE, Sigthorsson G, Oddson E, Gudjonsson H, et al. A randomised, double blind, double dummy, crossover study of the effects of nimesulide and naproxen on the gastrointestinal tract and an in vivo assessment of their selectivity for cyclooxygenase 1 and 2. Gut 2001;48:339-348.
31. Sturges HF, Krone CL. Ulcerations and stricture of the jejunum in a patient of long-term indomethacin therapy. Am J Gastroenterol 1973;59:162-169.
32. Huber T, Ruchti C, Halter F. Non-steroidal anti-inflammatory drug-induced colonic structures: A case report. Gastroenterology 1991;100:1119-1122.
33. Fellows IW, Clarke JM, Roberts PF. Non-steroidal antiinflammatory drug-induced jejunal and colonic diaphragm disease: A report of two cases. Gut 1992;33:1424-1426.
34. Bombardiner C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
35. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomised controlled trial. Celecoxib Long-term Arthritis Study. JAMA 2000;284:1247-1255.
36. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288-292.
37. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG; Investigators. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole and placebo. Clin Gastroenterol Hepatol 2005;3:133-141.
38. Silverstein FE, Graham GY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis SG. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-249.
39. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-2110.
40. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-366.
41. Aabakken L, Osnes M. 51 Cr-Ethylenediaminetetraacetic acid absorption test. Effects of naproxen, a non-steroidal, antiinflammatory drug. Scand J Gastroenterol 1990;25:917-924.
42. Matsumoto T, Kudo T, Esaki M, Yano T, Yamamoto H, Sakamoto C, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: A Japanese multicenter study. Scand J Gastroenterol 2008;43:490-496.
43. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172-1178.
44. Maiden L, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, Bjarnason I. Long-term effects of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: A cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007;5:1040-1045.
45. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005;3:55-59.
46. Gomez-Rodriguez B, Caunedo-Alvarez A, Romero-Vasquez J, et al. NSAIDs erosive enteropathy assessed by capsule endoscopy: A prospective controlled trial (abstract). Gastroenterology 2004;126:A96.
47. Vane JR. Towards a better aspirin. Nature (Lond) 1994;367:215-216.
48. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 2004;364:665-674.
49. Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, Bjarnason I. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000;47:527-532.
50. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl 1996;102:9-21.
51. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002;122:1913-1923.
52. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, et al. Prostaglandin synthase 1 gene disruption in mice reduced arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-492.
53. Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-714.
54. Mitchell J, Evans T. Cyclooxygenase-2 as a therapeutic target. Inflamm Res 1998;47(suppl 2):S88-S92.